2018
Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
Kanter J, Tisdale J, Kwiatkowski J, Krishnamurti L, Mapara M, Schmidt M, Miller A, Pierciey F, Shi W, Ribeil J, Walters M, Thompson A. Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial. Blood 2018, 132: 1080. DOI: 10.1182/blood-2018-99-113477.Peer-Reviewed Original ResearchSevere sickle cell diseaseGroup B patientsSickle cell diseaseGroup A patientsB patientsAdverse eventsGroup ALast visitTotal bilirubinBluebird BioHematopoietic stem cellsA patientsPeripheral bloodBusulfan conditioningReticulocyte countTotal HbVeno-occlusive liver diseaseAdvisory CommitteeMedical directorsNormalization of HbVaso-occlusive painSerious adverse eventsLong-term followPhase 1 trialSignificant clinical benefit
2006
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood & Cancer 2006, 47: 907-913. PMID: 16496290, DOI: 10.1002/pbc.20791.Peer-Reviewed Original ResearchConceptsElevated tricuspid regurgitant velocityTricuspid regurgitant velocitySickle cell diseaseAcute chest syndromePulmonary hypertensionCerebrovascular diseaseVasoocclusive crisisSCD patientsReticulocyte countCell diseaseType of SCDTricuspid regurgitant jet velocityLife-threatening complicationsObstructive sleep apneaPediatric SCD patientsRegurgitant jet velocityElevated reticulocyte countSignificant differencesNumber of echocardiogramsChest syndromeEchocardiographic evidenceOutpatient echocardiogramMean hemoglobinClinical characteristicsHydroxyurea therapy